Sanofi signed a multi‑year collaboration with Earendil Labs valued up to $2.56 billion to discover bispecific antibodies for autoimmune diseases using Earendil’s AI platform. The pact includes upfront and milestone payments and tiered royalties; Sanofi will lead clinical development and commercialization. Earendil framed the deal as validation of its AI discovery engine and Sanofi’s commitment to next‑generation biologics for immune disorders.